Relay Therapeutics (RLAY) Fundamental Analysis: Revenue, Earnings & Valuation

6.14 / 10

Outperform

Fundamentally, RLAY rates Outperform with a 6.1/10 rating. Strengths include Asset‑MV, Revenue‑MV, Profit‑MV, Cash‑MV, inventory turnover and gross margin. Weak points are low current and fixed asset turnover and a modest income‑tax‑to‑profit ratio.

Analysis Checks(7/10)

Revenue-MV

Value-3.32

Score2/3

Weight15.91%

1M Return8.05%

Inventory turnover ratio

Value106.57

Score3/3

Weight13.76%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score2/3

Weight2.92%

1M Return1.67%

Profit-MV

Value0.68

Score2/3

Weight12.94%

1M Return6.36%

Income tax / Total profit (%)

Value22.35

Score1/3

Weight0.32%

1M Return0.21%

Current assets turnover ratio

Value0.02

Score0/3

Weight-2.42%

1M Return-1.61%

Fixed assets turnover ratio

Value0.31

Score1/3

Weight-1.68%

1M Return-1.13%

Cost of sales ratio (%)

Value57.03

Score3/3

Weight6.84%

1M Return4.08%

Asset-MV

Value-0.55

Score3/3

Weight38.73%

1M Return15.70%

Cash-MV

Value0.03

Score2/3

Weight12.68%

1M Return6.19%

Is RLAY fundamentally strong?

RLAY scores 6.14/10 on fundamentals and holds a Discounted valuation at present. Backed by its -41.12% ROE, -1800.58% net margin, -6.21 P/E ratio, 3.03 P/B ratio, and 31.78% earnings growth, these metrics solidify its Outperform investment rating.